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Abstract Transglutaminase 2 (TG2) is a pleiotropic
enzyme involved in both intra- and extracellular processes.
In the extracellular matrix, TG2 stabilizes the matrix by
both covalent cross-linking and disulﬁde isomerase activ-
ity. These functions become especially apparent during
matrix remodeling as seen in wound healing, tumor
development and vascular remodeling. However, TG2
lacks the signal sequence for a classical secretory mecha-
nism, and the cellular mechanism of TG2 secretion is
currently unknown. We developed a green ﬂuorescent TG2
fusion protein to study the hypothesis that TG2 is secreted
via microparticles. Characterization of TG2/eGFP, using
HEK/293T cells with a low endogenous TG2 expression,
showed that cross-linking activity and ﬁbronectin binding
were unaffected. Transfection of TG2/eGFP into smooth
muscle cells resulted in the formation of microparticles
(MPs) enriched in TG2, as detected both by immunoﬂuo-
rescent microscopy and ﬂow cytometry. The fraction of
TG2-positive MPs was signiﬁcantly lower for cross-link-
ing-deﬁcient mutants of TG2, implicating a functional role
for TG2 in the formation of MPs. In conclusion, the current
data suggest that TG2 is secreted from the cell via micro-
particles through a process regulated by TG2 cross-linking.
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Abbreviations
C277S Transamidation-defective mutant of
transglutaminase 2
FBS Fetal bovine serum
FN Fibronectin
FSC Forward scatter (in ﬂow cytometry)
MOVAS Mouse vascular smooth muscle cell line
MP Microparticle
TG2 Transglutaminase 2
SEM Standard error of the mean
SMC Smooth muscle cell
SSC Side scatter (in ﬂow cytometry)
W241A Transamidation-defective mutant of
transglutaminase 2
Introduction
Transglutaminases (TGs) constitute a family of enzymes
involved in post-translational modiﬁcation of proteins
through transamidation (Aeschlimann and Thomazy 2000;
Collighan and Grifﬁn 2009; Di Pierro et al. 2010). In
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subtypes of TGs all exhibit very speciﬁc cellular functions
(Grifﬁn et al. 2002; Lorand and Graham 2003), which
depend strongly on subcellular localization (Park et al.
2010). Intracellularly, TG2 plays a role in signaling by
acting as a G-protein (Chen and Mehta 1999) and in
cytoskeleton organization, partly regulated by interaction
with membrane-bound heparan sulfate proteoglycans
(Telci et al. 2008; Sun et al. 2008; Verderio et al. 2009).
Extracellularly, TG2 mediates cell adhesion in cooperation
with ﬁbronectin and integrins (Verderio et al. 2003;
Zemskov et al. 2006; Forsprecher et al. 2009) and supports
the polymerization of ﬁbronectin and collagen (Jones et al.
1997; Akimov and Belkin 2001b; Yuan et al. 2007). These
TG2 effects have been linked to a variety of (patho)phys-
iological conditions (Chen and Mehta 1999; Lorand and
Graham 2003; Park et al. 2010). As an example, we pre-
viously showed that TG2 plays a key role in vascular
inward remodeling, a process occurring in hypertension
and hypoperfusion (Bakker et al. 2005, 2006, 2008).
In many cell types, the main pool of TG2 is cytosolic
under physiological conditions (Grifﬁn et al. 2002; Lorand
and Graham 2003). Cross-linking of matrix proteins, as
observed in tissue remodeling, requires transportation of
TG2 to the cell membrane and subsequently secretion into
the extracellular space. However, TG2 does not possess a
signal sequence to the ER/Golgi and is therefore believed
to follow a non-classical secretory pathway (Gaudry et al.
1999a, b; Akimov and Belkin 2001a, b; Collighan and
Grifﬁn 2009). Several prerequisites for cellular secretion
have been established. Thus, TG2 translocation requires
the active site cysteine, an intact N-terminal b-sandwich
domain and a non-proline cis-peptide bond at tyrosine-274,
which is near the active site (Gaudry et al. 1999a, b; Grifﬁn
et al. 2002; Balklava et al. 2002; Telci et al. 2008).
Sequestration of TG2 into the pericellular matrix is medi-
ated by ﬁbronectin (FN) binding (Gaudry et al. 1999a;
Scarpellini et al. 2009). Indeed, after truncation of the FN-
binding site at the N-terminus, TG2 is absent from the cell
surface (Gaudry et al. 1999a) or greatly lowered in cell-
conditioned media (Johnson and Terkeltaub 2005). In
addition, immunostainings reveal that membrane trafﬁck-
ing is often observed at sites where b1 integrins or heparan
sulfate proteoglycans are present (Verderio et al. 2009;
Scarpellini et al. 2009). Possibly, post-translational modi-
ﬁcation through N-acetylation serves as a secretion signal
(Muesch et al. 1990). However, despite this information,
the exact process of TG2 release remains unclear.
A possible route for externalization of TG2 is the for-
mation of microparticles (MP). MPs are released mem-
brane vesicles that are actively involved in normal
physiology and numerous diseases (VanWijk et al. 2003).
MPs can contain cytoplasmic components and surface
proteins from the cell they originate from. Carrying these
components, MPs can affect the local environment such as
the atherosclerotic plaque or act as a long-distance mes-
senger when secreted into the bloodstream (Martinez et al.
2005; Burnier et al. 2009). MPs are released during speciﬁc
cell activation such as seen with thrombin for platelets or
after cell apoptosis. Calcium plays a crucial role in release,
initiating the rapid loss of membrane phospholipids
asymmetry and dissociation of actin from membrane gly-
coproteins (VanWijk et al. 2003; Burnier et al. 2009). MPs
originating from platelets, erythrocytes, leukocytes and
endothelial cells have been related to vascular function,
remodeling, angiogenesis, hemostasis, thrombosis and
cardiovascular diseases such as atherosclerosis and colla-
gen vascular disorders (Nguyen et al. 1998; VanWijk et al.
2003; Martinez et al. 2005; Shah et al. 2008; Burnier et al.
2009; Bobik 2010; Chironi et al. 2010). More recently,
smooth muscle cells were identiﬁed as a source of MPs,
which seem to be active mainly within the vascular wall
(Schecter et al. 2000; Brisset et al. 2003; Aras et al. 2004;
Essayagh et al. 2005; Stampfuss et al. 2006; Leroyer et al.
2007).
In this study, we investigated the hypothesis that cellular
secretion of TG2 occurs via microparticles. In order to
track TG2 in MPs, we developed ﬂuorescently tagged TG2
proteins with intact cross-linking activity and ﬁbronectin
binding. Secretion of MPs enriched in TG2 was studied in
smooth muscle cells (SMCs), using time-lapsed ﬂuores-
cence microscopy and ﬂow cytometry. We found not only
evidence for the secretion of TG2 from SMCs via MPs, but
also that release of MPs is likely to depend on cross-linking
activity of TG2.
Materials and methods
Expression vectors
The IMAGE clone 3256943 (GenBank: BC016492)
for mouse TG2 was obtained from imaGenes (Berlin,
Germany). Using standard molecular biology techniques,
nucleotides 67–2,153, encompassing the complete TG2
open reading frame, were cloned into pCMV-SPORT6 to
obtain a non-tagged TG2 expression vector. Alternatively,
nucleotides 67–2,150 were cloned into pEGFP-N1 (Clon-
tech 632469) or pmCherry-N1 (Clontech 632523), gener-
ating vectors that express TG2 with a C-terminal ﬂuorescent
tag. The construction of ﬂuorescent TG2 expression vectors
is discussed in detail in the Supplementary text and Table 1.
Two different point mutations were used to inhibit trans-
glutaminase activity. Mutating the active site cysteine
(C277S) was already frequently employed to abolish TG2
activity (Akimov et al. 2000; Akimov and Belkin 2001b;
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123Balklava et al. 2002). This mutation is accompanied by
greatly impaired GTP binding, thereby changing the intra-
cellular conformation of TG2 (Liu et al. 2002; Ruan et al.
2008; Gundemir and Johnson 2009). Mutation of the tryp-
tophan residue bridging the hydrophobic tunnel next to the
active site, W241A, was reported to completely abolish TG
activity as well (Pinkas et al. 2007; Gundemir and Johnson
2009). With this mutation, GTP binding is retained, sug-
gesting that TG2 conformation is only adapted very locally
near the active site (Murthy et al. 2002; Gundemir and
Johnson 2009). Transamidation-defective mutants of TG2/
eGFP were created with the QuikChange XL-Site directed
mutagenesis kit (Agilent Technologies, 200516) according
to the manufacturer’s protocol. Oligonucleotide primers
used for creating mutant TG2-C277S/eGFP were 50-gaa
gtacgggcagtcctgggtgtttgcag-30 and 50-ctgcaaacacccaggact
gcccgtacttc-30. For mutant TG2-W241A/eGFP, 50-gtgcttc
tgggccgcgcggacaacaactatgg-30 and 50-ccatagttgttgtccgcgc
ggcccagaagcac-30 were employed. All cDNA sequences
were veriﬁed by DNA sequencing.
In several experiments, pEGFP-N1 and pmCherry-N1
were used as transfection controls.
Cell culture and transfection
HEK/293T cells (ATCC CRL-11268) and smooth muscle
cells (MOVAS, ATCC CRL-2797) were cultured in Dul-
becco’s modiﬁed Eagle’s medium (DMEM, Invitrogen)
containing 10% fetal bovine serum (Gibco) and a mix of
antibiotic–antimycotic (Gibco). One day before transfec-
tion, cells were seeded at about 60% conﬂuency in 12-well
plates. HEK/293T cells were transfected using Effectene
(Qiagen), according to the manufacturer’s instructions. The
ratio of DNA to Effectene Reagent used was 1 lg–20 ll.
Smooth muscle cells were transfected using Lipofectamine
LTX (Invitrogen, 15,338), according to the manufacturer’s
protocol. Per well, 1 lg DNA, 2.5 ll Lipofectamine LTX
and 1.0 ll PLUS reagent were used. Expression of TG2
fusion proteins was assessed by Western blotting, which is
described in detail in the Online Supplement.
TG2 activity assay
TG2 activity was measured using a colorimetric microas-
say (Covalab). HEK/293T cells were lysed in 0.01 M
TRIS, 0.15 M NaCl, 1 mM EDTA, 1 mM DTT, 0.1%
Triton X-100 and 1 tablet of protease inhibitors (Roche
11873580001), dissolved in a total volume of 50 ml. After
a sonication period of 10 s, lysis continued for 10 min on
ice and samples were centrifuged 15 min at 18.890g at
4C. The protein concentration in the supernatant was then
determined using the Bradford assay, and samples were
stored at -80C until further usage.
Cell lysates, together with biotin–cadaverine as amine
donor, were added to a 96-well plate to which an amine
acceptor was covalently coupled. TG2, which is activated
with calcium and dithiothreitol, then cross-links donor and
acceptor. In the second step, biotin is linked to streptavidin-
labeled peroxidase. In turn, peroxidase activity is revealed
using H2O2 and tetramethyl benzidine (el Alaoui et al.
1991). Finally, absorbance is read at 450 nm. The relative
activity of TG2 in cellular lysates was compared to
absorbance values measured for different concentrations of
TG2 isolated from guinea pig liver (Sigma T5398).
Immunostaining of TG2 and ﬁbronectin
For the immune-ﬂuorescent detection of TG2 and ﬁbro-
nectin, cells were trypsinized and reseeded in microscopic
culture chambers (BD Falcon 354,102, untreated glass).
After 24 h, cells were washed with warm PBS and ﬁxated
with formaline (20 min on ice). Cells were permeabilized
with 0.05% Triton X-100 and blocked with 3% BSA/5%
goat serum. Samples were then incubated for 1 h at room
temperature with either a rabbit polyclonal TG2 antibody
Ab-4 (Neomarkers RB-060-P, 1:10) or a rabbit polyclonal
ﬁbronectin Ab-23750 (Abcam, 1:400). Subsequently, anti-
rabbit Cy3 (Brunschwig 111-165-144, 1:200, respectively,
1:300) was used as secondary antibody, and slides
were mounted in Vectashield/DAPI (Vector Laboratories
H-1500).
Table 1 Number of extracellular ﬂuorescent TG2 particles on different substrates
Substrate Extracellular ﬂuorescent TG2 particles
(average number per cell)
TG2 eGFP sGFP
Plastic 0.50 ± 0.17 Not determined
Fibronectin 0.47 ± 0.27 Not determined
Collagen type I 14.0 ± 2. 81* 0.75 ± 0.36
HEK/293T cells were transfected with TG2/eGFP and reseeded on untreated glass, a coating of ﬁbronectin or collagen type I
Extracellular particles are given in average per cell ± standard error of the mean
* P\0.01 (collagen type I vs. glass or ﬁbronectin)
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eGFP-positive cells were randomly selected before the red
Cy3 signal was visualized using a Leica confocal micro-
scope (TCS SP2). These two ﬂuorescence images were
obtained in sequential mode, in which the blue excitation
for eGFP was shut off during recording of the red Cy3
image. This was done in order to prevent any possible
contribution of eGFP to the red signal. We established that
such cross-talk was indeed absent for the used confocal
settings. In order to quantify the degree of colocalization
between two 12-bit images, the Pearson correlation coef-
ﬁcient was calculated for each pair of images using Matlab
software, excluding all background pixels. Subsequently,
the correlation coefﬁcients were averaged over a number of
cells.
Cellular localization of TG2
Both intra- and extracellular TG2 localization were studied
in detail using cells incubated either on glass, ﬁbronectin or
collagen type I substrates. A ﬁbronectin coating was made
by 1-hr incubation at 37Co f7 5llo f1 0lg/ml ﬁbronectin
solution per compartment of the microscopic culture
chamber. Collagen type I (MP Biomedicals 160084, bovine
skin) was dissolved in acetic acid at 4C. Then, the pH was
elevated with a mixture of 1 M HEPES–NaOH and 2 M
NaOH, and 120 ll of this collagen solution (1 mg/ml) was
poured into a microscopic chamber and allowed to poly-
merize for 1 h at 37C. Cells were transfected with TG2/
eGFP or control eGFP and reseeded into microscopic
chamber slides.
For confocal microscopy, HEK/293T cells were incu-
bated for 24 h and formaline ﬁxed as described above. For
quantiﬁcation of extracellular TG2, eGFP-positive cells
were randomly selected. Images of these cells were taken
at a 40x-magniﬁcation, and all eGFP-positive extracellular
spots were counted in a 200 lm perimeter of the cell
nucleus. Differences in the number of vesicles when seeded
on glass, ﬁbronectin and collagen type I were tested for
statistical signiﬁcance using a 1-way ANOVA with Bon-
ferroni post hoc test.
Time-lapsed imaging was performed using a CO2 and
temperature controlled setup described in detail elsewhere
(Krawczyk et al. 2008; Stap et al. 2008). In short, MOVAS
SMCs were seeded onto ﬁbronectin-coated, chambered
coverglass (Lab-Tek II, Nunc 155379) and imaged with a
Leica inverted ﬂuorescence microscope using a 63x oil
objective. A motorized stage enabled imaging of a large
set of cells, with typically 1 auto-focused phase contrast
and 9–11 ﬂuorescence images at different cell heights
(step size: 400 nm). Vertical stacks were processed with
Huygens Pro deconvolution software (Scientiﬁc Volume
Imaging, the Netherlands) to enhance image contrast.
Flow cytometry
The typical diameter of MPs is between 100 nm and 1 lm.
Consequently, the size of MPs is in the order of and even
below the resolution of optical microscopy. Furthermore,
the ﬂuorescence intensity of individual MPs approaches the
detection limit of ﬂuorescence confocal microscopy (Van
Der Pol et al. 2010). Therefore, a quantitative assessment
of TG2-dependent MP release and secretion of TG2 by MP
was made using ﬂow cytometry. The size of SMC-derived
MPs was then estimated by comparing the light scattering
intensity with beads of known size. The scattering intensity
depends on size, shape and refractive index of a particle.
The refractive index of vesicles is unknown, but is likely to
be in the order of 1.4 (Van Der Pol et al. 2010). Therefore,
we selected silica beads with a diameter of 500, 1,000 and
5,000 nm (Kisker Biotech) and a refractive index of
approximately 1.46 for the wavelength of 488 nm used
(Medhat et al. 2002).
About 24 h after the start of the transfection protocol,
cells were washed and 1 ml of fresh medium was added.
Secretion of microparticles was stimulated with either 10%
FBS for 24 h or the calcium ionophore A23187 (5 lM) in
serum-free medium for 2 h. Culture supernatant was then
collected, and cell debris was removed by centrifuging for
15 min at 200g at 4C (Shirk et al. 1996). The top 700 ll
supernatant was then snap-freezed in liquid nitrogen and
stored at -80C until further use.
At the day of measurement, samples were thawed in ice
water and centrifuged for 60 min at 18.890g at 20C. The
top 650 ll supernatant was discarded, and the pellet was
resuspended in 200 ll 0.22 lm ﬁltered PBS. Samples were
centrifuged again at 18.890g for 30 min, and 215 ll
supernatant was discarded. Then, 10.0 ll of the resus-
pended microparticle pellet was diluted in 80 ll ﬁltered
PBS with 2.5 mM CaCl2. This was incubated for 15 min
together with 10 ll APC-tagged Annexin-V (Caltag Lab-
oratories, AnnexinV05, prediluted 40x) that binds to
phosphatidylserine groups exposed on the surface of MPs
(Brisset et al. 2003; Aras et al. 2004; Leroyer et al. 2007;
Bobik 2010). Speciﬁcity of Annexin-V binding was
checked by incubating MPs in calcium-free PBS supple-
mented with 0.32% citrate.
Samples were analyzed using a Calibur ﬂow cytometer
(Becton–Dickinson). Forward scatter (FSC), side scatter
(SSC) and ﬂuorescence were set in a logarithmic scale.
Events were ﬁrst gated using the FSC and SSC signals and
MPs were identiﬁed as described previously (Nieuwland
et al. 1997). Subsequently, the APC signal from Annexin-
V, thresholded using the negative control, was used to
conﬁrm the selected MPs. Transfected TG2 was identiﬁed
in these particles using the eGFP signal, for which thres-
holding was set using a non-transfected control sample.
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protein and MP ﬂuorescence intensities were tested with a
1-way ANOVA with Bonferroni post hoc test.
Results
Transamidation activity is unaffected in ﬂuorescently
tagged TG2
Upon transfection, 95–99% of the HEK/293T cell popu-
lation expressed the transfected TG2. Expression of TG2
with or without ﬂuorescent tags (eGFP or mCherry) was
not signiﬁcantly different, as determined from quantiﬁca-
tion of Western blots (Supplemental Fig. 1 and Table 2).
Non-modiﬁed TG2 showed a strong band at 80 kDa, while
TG2/eGFP was present at the expected size of 110 kDa.
However, in addition to the 110 kDa band, about half of
the TG2/mCherry fusion product was observed at 90 kDa.
These data are presented and discussed in detail in the
Online Supplement. Because of this partial degradation of
TG2/mCherry, all subsequent experiments were carried out
using TG2/eGFP.
Transglutaminase activity of cell lysates from TG2
transfectants was measured in vitro, using incorporation of
biotin–cadaverine. Activity as expressed per microgram
total protein was not statistically different between ﬂuo-
rescently tagged and untagged TG2 (Supplemental
Table 1). Background activity was zero in non-transfected
or eGFP-transfected HEK/293T cells. In lysates from
HEK/293T cells transfected with TG2/eGFP containing
one of the inactivating mutations C277S or W241A,
transamidation activity was absent as well.
Immunostaining conﬁrms localization
of TG2 for TG2/eGFP
In order to assess whether the ﬂuorescent signal indeed
represented TG2, transfected HEK/293T cells were
immunostained for TG2 (Fig. 1a–d). This revealed a strong
colocalization between eGFP and the Cy3-labeled TG2
antibody, which was quantiﬁed by a Pearson correlation
coefﬁcient of 0.78 ± 0.04 (P\0.01) for a representative
selection of 12 cells (Fig. 1e, f). Omission of the primary
TG2 antibody resulted in virtual absence of immunostain-
ing and lack of colocalization with eGFP (r =- 0.13 ±
0.13, P = NS, data not shown).
Immunostaining conﬁrms interaction of TG2/eGFP
with ﬁbronectin
The ﬁbronectin-binding site of TG2 is known to mediate
the secretion of TG2. The binding between TG2 and
ﬁbronectin was studied by immunostaining HEK/293T
cells transfected with TG2/eGFP. Figure 2 shows a repre-
sentative example, where 2 of the 4 cells were expressing
TG2/eGFP. As can be seen, ﬁbronectin staining was only
visible in the cells expressing TG2. Indeed, TG2 strongly
colocalized with ﬁbronectin, with a Pearson correlation
coefﬁcient of 0.69 ± 0.04 (P\0.01) for a collection of 16
transfected cells.
Fig. 1 Colocalization of TG2/eGFP and immunostaining for TG2.
HEK/293T cells were transfected with TG2/eGFP and reseeded on
glass slides. After ﬁxation, these cells were immunostained for TG2,
which was visualized with Cy3 secondary antibody. a Through
d show, respectively, DAPI staining, DIC image, TG2/eGFP and Cy3.
e Fluorogram for the overlay between green and red as shown in f,
where for both channels the 12-bit intensities ranging from 0 to 4,095
are plotted against each other pixelwise. For a collection of 12 cells,
the average Pearson correlation coefﬁcient was 0.78 ± 0.04 between
the green and red channels
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in HEK/293T cells
Subcellular localization of TG2/eGFP was ﬁrst studied on
HEK/293T cells cultured on different substrates. When
cells were seeded on glass (Fig. 2) or ﬁbronectin (Sup-
plemental Fig. 2), TG2 was distributed homogeneously
throughout the perinuclear space. Seeding on collagen type
I resulted in differential localization of TG2 between the
base and top of the cell. At the adherent side, eGFP ﬂuo-
rescence revealed an elongated network of TG2 bound to
ﬁbrils of unknown origin (Fig. 3c). At the top side, TG2/
eGFP appeared more concentrated as distinct spots
(Fig. 3b). Although we could not discern whether these
vesicles were localized intra- or extracellularly, the largest
spots often appeared at the cell membrane, where they
possibly are in the process of externalization (Fig. 3a).
Under high excitation intensity, TG2/eGFP vesicles were
also observed at distances up to 200 lm from the cell
membrane (Fig. 3d, e). We believe that these large vesicles
consist of aggregates of microparticles, since at high-
magniﬁcation multiple green centers could be discerned
within one spot (insert in Fig. 3e). For TG2/eGFP
expressing cells seeded on glass or ﬁbronectin, these
extracellular vesicles were virtually absent (see Table 1).
This substrate-dependent release of the ﬂuorescent con-
struct was not found in control experiments where only
eGFP was transfected in cells seeded on collagen.
Smooth muscle cells secrete microparticles enriched
in TG2
As was the case for the HEK/293T cells, in transfected
MOVAS cells, TG2/eGFP accumulated in vesicles that
were found especially at the boundary of the cell (Fig. 4,
open arrows). These spots often disappeared suddenly
within minutes after their appearance. Occasionally, such a
spot was observed to transform into a large membrane
vesicle that was released from the intact cell (Fig. 4, closed
arrows).
SMCs did not produce MPs when serum was withdrawn
from the culture medium for a short period of time. Thus,
after 2 h serum deprivation, MPs were virtually undetect-
able. In the presence of serum, however, SMCs continu-
ously produced MPs, as measured by ﬂow cytometry. By
comparing the FSC–SSC signal of beads of known sizes
and a similar refractive index, the size of SMC-derived
MPs was estimated to be between 500 and 1,000 nm
(Supplemental Fig. 4). Figure 5a–d shows an example of
MP production by TG2/eGFP transfected cells after 24 h of
Fig. 2 Immunostaining of ﬁbronectin for HEK/293T cells transfected
with TG2/eGFP and reseeded on glass. a–c Shown is a cluster of 4
cells, 2 of which show a high expression of TG2/eGFP (c). TG2
colocalizes with ﬁbronectin, which was immunostained and
visualized with cy3 secondary antibody, as shown in red (d). For a
collection of 16 cells, the Pearson correlation coefﬁcient was
0.69 ± 0.04 between the green and red channels
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123serum stimulation. In 5a, MPs and other small fragments
were separated from cell debris based on low forward and
side scattering. This fraction was then gated according to
Annexin-V labeling to positively identify microparticles
(5b).The non-speciﬁc binding of Annexin-V in a citrate
buffer that lacked calcium amounted to only 0.5%. The
Annexin-V positive fraction was then analyzed for eGFP
intensity (5c). 5d correlates intensity of Annexin-V staining
with eGFP ﬂuorescence and demonstrates that 96–98% of
the eGFP-positive hits were MPs.
Figure 5e, f shows average numbers and ﬂuorescence
intensities of events classiﬁed as MP according to Fig. 5a,
b. Transfection with TG2/eGFP resulted in a strong con-
centration of TG2 into microparticles in the presence of
serum (5e, middle panel). While typically 16–18% of the
cells were successfully transfected with TG2/eGFP,
42.4 ± 2.8% (SEM) of all microparticles were positive for
TG2/eGFP. In contrast, transfection with control eGFP
resulted in 15.9 ± 1.4% eGFP-positive MPs, despite the
higher transfection efﬁciency (*25%) for eGFP as com-
pared to TG2/eGFP. The high number of TG2-enriched
MPs appeared to depend on the TG2 cross-linking activity,
since in both TG2 mutants the percentage of eGFP-positive
MPs was similar to the control eGFP group. In agreement
with the elevated eGFP-positive fraction for TG2/eGFP,
this group also displayed signiﬁcantly higher ﬂuorescence
intensity when averaged per MP (5e, bottom panel). We
considered that the higher eGFP signal in TG2/eGFP
transfected MP might simply be related to the formation of
larger MPs. However, Annexin-V intensity, as a marker of
MP surface area, was virtually identical in MPs derived
from TG2/eGFP-transfected cells as compared to cells
transfected with eGFP, TG2-C277S/eGFP and TG2-
W241A/eGFP, even though these values were slightly
higher than those from non-transfected cells (5e, top panel).
In addition, when ﬂow cytometry was performed at the level
of the intact cell, ﬂuorescence was about 4–5 times higher
for eGFP, as compared to both TG2/eGFP and its two
mutants. Thus, in order to override this effect, the higher
ﬂuorescence of TG2/eGFP in MPs must be due to a strong
mechanism of concentrating TG2 into microparticles.
This role of TG2 in MP formation during serum stimu-
lation could be mimicked by stimulation using the calcium
ionophore A23187 for 2 h. This resulted in a fraction of
31.5 ± 5.0% of the identiﬁed MPs that were positive for
TG2/eGFP. Both TG2 mutants were present in a smaller
fraction of the MPs (TG2-W241A/eGFP: 18.2 ± 3.2%,
P = 0.067 vs. TG2/eGFP; TG2-C277S: 14.8 ± 3.9%,
P\0.05). Control eGFP was identiﬁed in only 1.4 ± 0.2%
(5f, middle panel). The elevated fraction for TG2/eGFP as
compared to the TG2 mutants was accompanied by a higher
eGFP signal, although this did not reach statistical signiﬁ-
cance (5f, bottom panel). MP size, as estimated by Annexin-
V intensity, was not different over all groups (5f, top panel).
Discussion
This study showed that TG2 is secreted from smooth
muscle cells via microparticles (MPs). Moreover, we found
evidence that release of MPs depends on the cross-linking
Fig. 3 Subcellular localization of ﬂuorescent TG2 particles on
collagen type I. HEK/293T cells were transfected with TG2/eGFP
and reseeded on a coating of collagen type I. a Shows an example of a
typical top view, with concentrated TG2/eGFP particles both inside
and outside the cell boundaries. b Along the upper cell surface, bright
eGFP spots were visible throughout the perinuclear space. c At the
adherent side, TG2appeared partly asagreen meshwork. d–e Illustrate
extracellular TG2: A large cluster of TG2 particles (indicated by a
white arrow) was observed at a distance of 100–200 lm from the cell.
Examples in a–d were taken from different images
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123activity of TG2. Here, we address how the major tool for
these experiments, ﬂuorescently tagged TG2, was devel-
oped and validated. We then discuss the potential mecha-
nisms for TG2-dependent MP formation and depict the
relevance of the current ﬁndings for cell–matrix interac-
tion, in particular in the context of vascular remodeling and
disease.
We generated an expression vector encoding a ﬂuores-
cently tagged TG2 protein in order to study TG2 subcel-
lular localization and secretion. A few papers report the use
of ﬂuorescent transglutaminase, but to the best of our
knowledge these tagged proteins have not been used for
localization of TG2 in particular microenvironments.
Zainelli et al. (Zainelli et al. 2005) developed a N-terminal
TG2 fusion product, which was employed to identify TG2
substrates in Huntington disease in vitro. Recently, Jeong
et al. (Jeong et al. 2009) described the preparation of GFP-
traceable viruses containing TG2. Here, the GFP signal was
used to monitor TG2 expression level. Factor XIII, well
known for its role in blood coagulation, is another member
of the transglutaminase family. A recent paper by Jayo
et al. describes cloning of the active subunit of FXIII into a
GFP vector. The green cell protrusions containing FXIII
that were detected were postulated to be cell protrusions
active in motility via RhoA (Jayo et al. 2009).
We used HEK/293T cells for initial functional charac-
terization of eGFP-tagged TG2, because these cells have a
very low endogenous TG2 expression and are readily
transfected. Since it is clear that ﬂuorescent tagging may
affect functional properties of enzymes, we addressed
attention to two aspects of TG2 function. First, we estab-
lished that the eGFP-tagged TG2 retains its characteristic
cross-linking activity at a level comparable to that of the
wild type, while this was absent from both TG2 mutants
(Supplemental Table 1). A second critical property of TG2
is its ﬁbronectin-binding site, since this is indispensible for
TG2 secretion (Gaudry et al. 1999a). Fibronectin binding is
accomplished by the N-terminal amino acids 1–7 (Lorand
and Graham 2003) and 88–106 in TG2 (Collighan and
Grifﬁn 2009). We therefore chose to ﬂuorescently tag TG2
Fig. 4 Intracellular formation and secretion of microparticles
enriched in TG2. Smooth muscle cells were seeded on a coating of
ﬁbronectin and transfected with TG2/eGFP. The top panel shows the
phase contrast series, the lower panel the ﬂuorescence images after
deconvolution of a vertical image stack. Microparticles are visible
near the cell periphery at all time points, as indicated by open arrows.
The closed arrow points to a microparticle that is assembled and
subsequently released into the extracellular matrix
968 J. Van den Akker et al.
123at the C-terminus, which is mainly involved in receptor
signaling via adreno-receptors (Chen and Mehta 1999).
Indeed, it has previously been shown that fusion of the TG2
C-terminus to the reporter enzyme b-galactosidase had no
effect on interactions between TG2 and FN (Gaudry et al.
1999a). Another reason to prefer C-terminal tagging was
that N-acetylation has been proposed as a possible mech-
anism for TG2 externalization (Muesch et al. 1990). Our
eGFP-tagged TG2 showed a strong colocalization with
ﬁbronectin (Fig. 2), suggesting that TG2 binding to ﬁbro-
nectin had remained intact. We observed a rather uniform
distribution of ﬁbronectin throughout the cytoplasm. Since
we permeabilized the cells for immunostaining, this may
represent either membrane-bound ﬁbronectin or an intra-
cellular pool of this protein, originating either from cellular
synthesis or uptake from the serum used for culturing.
These results indicate that the N-terminus of our TG2/
eGFP construct has retained its characteristic ﬁbronectin-
binding site, which is critical for TG2 secretion (Johnson
and Terkeltaub 2005). A next step in the interaction
between TG2 and FN is ﬁbronectin polymerization into
networks (Jones et al. 1997; Akimov and Belkin 2001b;
Yuan et al. 2007). We could not detect whether such net-
works developed, mainly because of the strong signal
coming from what we believe is monomeric ﬁbronectin.
Since ﬁbrillogenesis was not the main issue of the current
study, this effect of the various TG2 constructs was not
further studied.
Using the functionally intact TG2/eGFP, we visualized
the subcellular distribution of TG2 ﬁrst in HEK/293T cells
and subsequently in SMCs. Vesicles, and especially
vesicular aggregates up to several micrometers in size,
became evident when TG2/eGFP transfected cells (SMC or
HEK) were cultured in a microenvironment of collagen
type I in the presence of serum. Using HEK/293T cells
transfected with TG2/eGFP and grown on ﬁbronectin or
glass, these structures were rarely observed by confocal
microscopy. However, live-imaging or ﬂow cytometry
measurements showed that MPs were produced irrespec-
tive of the substratum used during SMC culturing. There-
fore, the 3-D collagen matrix used with HEK/293T cells
seems to have functioned to entrap MPs, resulting in an
elevated number of observed MPs as compared to ﬁbro-
nectin and glass in our histological preparations. It remains
to be tested whether collagen ﬁbers could also bind the MP
Fig. 5 Secretion of TG2 via microparticles, quantiﬁed using ﬂow
cytometry. a–d Microparticles were identiﬁed ﬁrst by FSC and SSC
characteristics (region indicated with ‘‘SF’’) and subsequently by
Annexin-V/APC signal eGFP was thresholded using non-transfected
control cells. e–f There was no difference in MP size between the
various eGFP-positive proteins, as estimated by average intensity of
Annexin-V/APC. MPs were particularly enriched in TG2/eGFP
compared to eGFP, and both TG2 cross-linking mutants, both upon
stimulation with serum or calcium ionophore A23187. Average eGFP
ﬂuorescence was elevated for TG2/eGFP for both stimuli, which
reached signiﬁcance for the serum group. P-values are given with
respect to TG2/eGFP, unless indicated otherwise
b
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123or further stimulate the release of MP by interaction with
the native cells.
Our choice for serum and the calcium ionophore
A23187 as stimuli for the induction of MPs needs expla-
nation. It is clear that the exact serum component(s) caus-
ing release has not been identiﬁed, while the calcium
ionophore is an extremely strong stimulus with little rele-
vance for pathological conditions. Yet, it was not our
purpose to unravel signaling leading to MP release in
speciﬁc conditions, but rather to test the involvement of
TG2 in ﬁnal release, irrespective of upstream events. We
therefore used both serum and the calcium ionophore as
robust stimuli. Our ﬁnding that serum stimulation enhances
MP generation is in agreement with the activity of MP-
derived tissue factor that is virtually absent in quiescent
cultures of SMCs, ECs, ﬁbroblasts and macrophages
(Schecter et al. 2000). For the calcium ionophore, several
studies employed a 10 lM concentration for 10 min only
(Carson et al. 1994; Aras et al. 2004). We preferred to
prolong the incubation time to 2 h while lowering the dose
to 5 lM, since this is known to activate intracellular TG2
(Jeong et al. 2009), and in our hands greatly increased the
accumulated number of microparticles. Since Annexin-V is
a marker for both MPs and apoptotic bodies, it could be
argued that our results reﬂect increased apoptosis rather
than MP release. This is especially relevant because
transfection with TG2 sensitizes cells to apoptosis when its
transamidating activity is switched on, while it is protective
when transamidating activity is dormant, as in our mutant
TG2 (Tucholski and Johnson 2002; Fesus and Szondy
2005). While we cannot fully exclude the involvement of
apoptosis, the examples in Figs. 3 and 4 do not show any
signs of apoptosis, and neither was this seen during visual
inspection of the transfected cultures. In addition, time-
lapsed video microscopy following stimulation with
A23187 did not show clear apoptosis. A quantitative
analysis of the rate of apoptosis under the various condi-
tions is required to fully exclude this possibility. A possible
though challenging further approach would have been to
study the composition of the shed vesicles, e.g., for cyto-
solic organelles or nuclear fractions that are present in
apoptotic bodies but not MPs.
The initial rise of calcium activates TG2, but subsequent
calcium overload could induce the degradation of TG2 via
calcium-mediated poly-ubiquitination, keeping transami-
dating activity levels below the threshold of toxicity for
cells (Jeong et al. 2009). We have not studied such
mechanisms, but A23187 induced massive intracellular
transamidation activity in smooth muscle cells tested in
intact blood vessels (unpublished). In at least those
experiments, possible poly-ubiquitination was apparently
not effective or fast enough to prevent such undue intra-
cellular activity. Although A23187 was a tool for inducing
MPs, we believe that physiological stimuli for MP release
in situ would typically not require such high and long-
lasting elevation of calcium.
We based our conclusion that TG2 is released via mi-
croparticles, in a cross-linking-dependent manner, on the
comparison of MPs from SMCs transfected with TG2/
eGFP to control eGFP and two TG2 cross-linking mutants.
Unfortunately, we could not conﬁrm these experiments on
non-transfected cells, since the available antibodies against
mouse TG2 appeared not to be suited for ﬂow cytometric
measurements. This also prevented ﬂow cytometric testing
for TG2 release during pathological conditions such as
vascular remodeling. However, Western blotting on both
cell lysates and isolated microparticles showed that the
eGFP signal could indeed be used to track TG2 and that the
MPs contain an intact TG2/eGFP fusion protein (Supple-
mental Figs. 1 and 3).
We have not addressed whether the two TG2 cross-
linking mutants still have a normal ability for GTP cycling.
However, a few studies addressed GTP binding for
W241A. Immunoblotting of several TG2 mutants con-
vincingly showed that GTP binding is unaffected for
W241A (Gundemir and Johnson 2009). In addition, GTP-
gammaS caused a shift of both wild-type TG2 and TG2-
W241A toward more ‘‘fast moving’’ (or nucleotide-bound)
enzyme in non-denaturing electrophoresis (Murthy et al.
2002). Clearly, unimpaired binding to GTP does not nec-
essarily mean that GTP cycling is unaffected, and future
work will therefore be needed to conﬁrm that indeed the
cross-linking ability is crucial for MP formation.
GTP inhibits transamidation activity. There is little
reason to assume that GTP levels are falling following the
stimulation with serum or the calcium ionophore. Since the
mutant TGs are likely to have intact GTP binding, the clear
difference between wild type and mutants also points to
other factors activating TG2 than low GTP. We rather
believe that increased local calcium is crucial. A very
recent study by (Zemskov et al. 2011) supports this. These
authors showed that TG2 is targeted to perinuclear recy-
cling vesicles and is delivered inside these vesicles prior to
externalization. The calcium chelator BAPTA inhibits this
transport, while a calcium ionophore acts as stimulus.
These experiments show that calcium, possibly in these
perinuclear compartments, is crucial.
We propose the following hypothesis for the secretion of
TG2 from vascular cells. After cell activation, TG2 is
translocated to the cell membrane by perinuclear recycling
vesicles (Zemskov et al. 2011). We speculate that this
occurs preferably at sites of a5b1 and amb3 integrins,
which were frequently shown to colocalize with concen-
trated spots of TG2 (Gaudry et al. 1999b; Telci et al. 2008;
Zemskov et al. 2011). Interestingly, these integrins were
also identiﬁed at the surface of SMC-derived MPs involved
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123in tissue factor activation (Schecter et al. 2000). In addi-
tion, heparan sulfate proteoglycans such as syndecan-4
may function to recruit TG2 from the cytosol to these
membrane sites (Scarpellini et al. 2009). Based on the
enrichment of MP with mutant TG2 (Fig. 5f), we believe
that TG2 cross-linking is not required for this translocation.
Indeed, a recent paper by Antonyak et al. showed that after
transfection of HeLa cells with wild-type TG2 or mutant
TG2 defective in transamidation or GTP binding, all iso-
forms could be triggered to translocate to the cell mem-
brane upon stimulation with EGF (Antonyak et al. 2009).
Then, after transportation to the cell membrane, cross-
linking activity is likely to be required for release of these
TG2-enriched MPs. This would require a high calcium
level that is known to be locally present during the
development of MPs (VanWijk et al. 2003; Burnier et al.
2009). In support of this theory, upon transfection of 3T3
ﬁbroblasts with TG2 or C277S mutant, both forms were
detected on the cell surface, but only wild-type TG2 was
detected in the ECM and cell culture supernatant (Balklava
et al. 2002). Possibly, TG2 cross-linking activity is
required to link cytoskeletal elements that together form
the structural basis for the MP. This is similar to the setting
of lung cancer cells challenged by mechanical damage,
where TG2 was shown to promote membrane resealing
(Kawai et al. 2008). When pulmonary artery SMCs were
stimulated with serotonin, this induced transamidation of
proteins, which could be detected both in cells and their
culture supernatant. Three of the four major TG2 substrates
were found to be non-muscle myosin heavy chain, ﬁlamin
B and plakin (Liu et al. 2010), which are involved in the
stabilization of the cytoskeletal network to the cell mem-
brane (Leung et al. 2002). Correspondingly, Factor FXIII
may play the role in platelets that TG2 fulﬁlls in SMCs.
When stimulated with thrombin or calcium ionophore,
which are known to trigger MP generation (VanWijk et al.
2003), FXIII is transported to the platelet periphery within
1 min (Serrano and Devine 2002). After isolation from
the cytoskeletal fraction, ﬁlamin and vinculin were cross-
linked into multimeric complexes, which could be pre-
vented by preincubation with the transglutaminase inhibitor
iodoacetamide. Thus, transglutaminases clearly have a high
afﬁnity for cytoskeletal elements that may function as
building blocks for microparticles.
Future work is needed to substantiate the above mecha-
nisms for the secretion of TG2 from cells. In addition to
demonstrating unimpaired GTP cycling in the mutants, the
presence of newly formed isopeptide bonds in the MP
should be tested. Moreover, the effect of permeable TG2
inhibitors such as dansyl cadaverine on inhibition of MP
release ought to be tested. In pilot experiments, we tested
whether the active site inhibitor L682777 blocks MP
release. While we did not ﬁnd a clear inhibition, it is
questionable whether this inhibitor can penetrate the peri-
nuclear vesicles. In summary, we developed a green ﬂuo-
rescent TG2 protein to study the translocation and secretion
during vascular remodeling. Using HEK/293T cells, we
conﬁrmed that protein cross-linking and ﬁbronectin binding
of TG2 were unaffected by the eGFP tag. In smooth muscle
cells, TG2/eGFP was translocated to sites of vesiculation
near the cell periphery upon stimulation with a calcium
ionophore or a non-identiﬁed serum component. The cross-
linking function of TG2 appeared to be required for the
secretion of microparticles. This may provide the mecha-
nism for the activation, translocation and extracellular
activity of TG2 as seen in tissue remodeling and speciﬁcally
vascular remodeling (van den Akker et al. 2009).
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